The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 3 of the 8 sources its claims cite were checked for support.
Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions
Open accessAbstract
Psilocybin-producing mushrooms exhibit considerable biochemical diversity, yet the extent of variability among strains within a single species under standardized conditions remains insufficiently characterized. In this study, we quantified psilocybin, psilocin, baeocystin, norbaeocystin, aeruginascin, and norpsilocin in the fruiting bodies of 14 distinct strains of Psilocybe cubensis. The mushroom strains were cultivated, dried, extracted, and analyzed under uniform laboratory conditions. Despite strict methodological standardization, total tryptamine concentrations varied by more than 7.8-fold among strains (from 2.62 to 20.65 mg/g), with psilocybin consistently emerging as the dominant compound. Analysis of individual fruiting bodies within the selected strains revealed substantial intra-strain variability, with coefficients of variation for psilocybin ranging from 12.81% to 23.39% between individual fruiting bodies. These findings demonstrate that both inter- and intra-strain biochemical heterogeneity persist even under controlled conditions, underscoring the challenges of standardizing whole mushroom preparations for research or therapeutic use. Our results highlight the importance of strain selection, rigorous chemical profiling, and dosing precision in future pharmacological and clinical applications of P. cubensis.
Overview
CoChat Summary
TL;DR
In 14 *Psilocybe cubensis* strains grown under identical controlled conditions, total tryptamine content varied more than 7.8-fold (2.62–20.65 mg/g), with psilocybin dominant. Individual fruiting bodies within strains also varied substantially (psilocybin CV 12.81–23.39%), so species or strain identity alone did not predict psychoactive profile.
Key findings
- Total indole alkaloid concentrations varied by more than 7.8-fold across the 14 strains, from 2.62 mg/g in “Oak Ridge light” to 20.65 mg/g in “Mak IND.” Psilocybin was dominant in all strains and ranged from 2.03 ± 0.56 mg/g (“Oak Ridge light”) to 19.60 ± 2.93 mg/g (“Mak IND”).
- Other tryptamines showed strain-specific patterns: psilocin ranged from 1.77 ± 0.14 mg/g (“Penis Envy”) to 0.11 ± 0.03 mg/g (“Enigma”); baeocystin ranged from 0.43 ± 0.04 mg/g (“Sat”) to below the limit of detection (<LOD) in others; norbaeocystin and aeruginascin were detected only at low concentrations and frequently below the LOD. No consistent relationship was detected among compounds.
- Intra-strain psilocybin coefficients of variation among five individual fruiting bodies per strain ranged from 12.81% to 23.39%; the highest was approximately 23.39% for “Jack Frost × Shakti.”
- ITS sequencing confirmed all 14 strains as *P. cubensis*: ITS1 pairwise identity was 97.78–99.10% with query coverage 97–100%; ITS2 showed 100% identity for 13 of 14 strains and 99.42% for “Jack Frost,” with 100% query coverage. The negative control was distinct and identified as *Panaeolus cyanescens*.
Methods
- Fourteen *P. cubensis* strains from Psilution Ltd. and Wombat Labs were cultivated under standardized conditions: maintained on potato dextrose agar at 25 °C in the dark, grown on wheat/millet spawn, fruited in monotubs with coconut coir/vermiculite substrate under a 12 h light/dark cycle at >80% relative humidity, then harvested, lyophilized, and ground.
- Tryptamines were extracted from 100 mg (±5 mg) dry mushroom powder using methanol and acetic acid (99.5:0.5, v/v), incubated at 50 °C for 1 h, centrifuged, extracted a second time, and filtered. Psilocybin, psilocin, norbaeocystin, aeruginascin, baeocystin, and norpsilocin were quantified by HPLC–PDA; the limit of quantitation was 3 mg/L.
- Inter-strain comparisons used at least three technical replicates per strain from prepared powder. Intra-strain analysis used six randomly selected strains, with five individual fruiting bodies per strain extracted in triplicate; CV was calculated for psilocybin. ITS1/ITS2 sequencing, BLAST, and T-COFFEE alignment were used for species confirmation.
Limitations
- Stated: all strains were cultivated under a single standardized protocol at 25 °C, which may not represent optimal growth conditions for every strain; future studies should investigate strain-specific substrate composition, temperature, humidity, and container volume.
- Stated: comparisons with prior literature are difficult because of methodological heterogeneity in growth conditions, drying, solvents, extraction time and temperature, and analytical instruments; no comprehensive genetic reference database for these strains was available, so phenotypic verification was used with care.
- Evident: intra-strain variability was assessed for only six of the 14 strains and only psilocybin CVs are reported, so within-strain patterns for other tryptamines are not characterized. The design also cannot disentangle genetic from environmental or developmental causes of the observed variation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
3 Valid · 0 Not valid · 1 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The tryptamine concentration in the “Mak IND” strain is higher than previously reported for other P. cubensis strains [4,11,12].”
§ Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions > 4. Discussion
What the sources say
- Partly supportedcites [4] Kurzbaum, E., Páleníček, T., Shrchaton, A., Azerrad, S., and Dekel, Y. (2025). Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps. J. Fungi, 11. sourceExperimental — accuracy not yet measured
Section 2, “Strain Variability” (page unavailable), reports tryptamine-related compound concentrations across other P. cubensis strains, providing comparison data. It does not report a concentration for Mak IND or establish that Mak IND exceeds those strains; searches for “Mak IND” and the claimed comparison found no such passage. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [11] Goff, 2024, Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography-tandem mass spectrometry, Anal. Chim. Acta source
- Not matchedcites [12] Stijve, 1993, Macromycetes from the State of Paraná, Brazil. 4. The Psychoactive Species, Arq. Biol. Tecnol.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the strain Jack Frost × Shakti exhibited the highest CV of approximately 23.39%.”
§ Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions > 3. Results > 3.2. Intra-Strain Variability in Tryptamine Content Among Individual Fruiting Bodies Across Selected P. cubensis Strains
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Psilocin ranged from 1.77 ± 0.14 mg/g in “Penis Envy” to 0.11 ± 0.03 mg/g in “Enigma””
§ Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions > 3. Results > 3.1. Tryptamine Content Variability Across 14 P. cubensis Strains Cultivated Under Identical Controlled Conditions
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the negative control exhibited substantially lower similarity, with 75.81% identity and 25% query coverage, indicating clear divergence from the P. cubensis group.”
§ Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions > 3. Results > 3.3. Species Confirmation of P. cubensis Strains by ITS Sequencing
boostedSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“confirm that all investigated strains belong to a single species, P. cubensis.”
- Also stated in: § 3.3. Species Confirmation of P. cubensis Strains by ITS Sequencing · boosted
“provides strong molecular evidence that all investigated strains belong to the same species, P. cubensis.”
§ Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions > 2. Materials and Methods > 2.5. Molecular Confirmation of P. cubensis Strains by ITS Sequencing
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.3. Species Confirmation of P. cubensis Strains by ITS Sequencing · boosted
16 more claims
Create a free account to see all 37 claims and to verify the 1 reference still open.
- Borderline: one of the tests for a substantial claim is unclear. 1
- It may state two separate claims as one. 14
- The quote only partly states this claim. 1
- Probably not a substantial claim. 3
Citations
Cites
Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics
White, T. J., Bruns, T., Lee, S., & Taylor, J. (1990) · PCR Protocols · doi:10.1016/b978-0-12-372180-8.50042-1 · Cited by 36,648
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167 · cited 2×
“To date, most clinical trials investigating psilocybin have utilized pure synthetic formulations, such as those from Compass Pathways [20] or the Usona Institute [21].”
Self-citationLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.14530 · Cited by 545 · cited 1×
“To date, most clinical trials investigating psilocybin have utilized pure synthetic formulations, such as those from Compass Pathways [20] or the Usona Institute [21].”
Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073759 · Cited by 425
Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim
Hofmann, A., Heim, R., Brack, A., & Kobel, H. (1958) · Experientia · doi:10.1007/bf02159243 · Cited by 282
Therapeutic use of psilocybin: Practical considerations for dosing and administration
MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1040217 · Cited by 128 · cited 2×
“Clinical dosing of psilocybin spans a broad spectrum: sub-perceptual microdoses (around 2.5 mg), low doses (5–15 mg), standard therapeutic doses (20–25 mg), high doses (25–30 mg), and supra-therapeutic doses (above 35 mg) used to evaluate safety thresholds [24].”
InfluentialVan Court, R. C., Wiseman, M. S., Meyer, K. W., Ballhorn, D. J., Amses, K. R., Slot, J. C., Dentinger, B. T. M., Garibay-Orijel, R., & Uehling, J. K. (2022) · Fungal Biology · doi:10.1016/j.funbio.2022.01.003 · Cited by 94
Li, N.-X., Hu, Y.-R., Chen, W.-N., & Zhang, B. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.041 · Cited by 72
Gotvaldová, K., Hájková, K., Borovička, J., Jurok, R., Cihlářová, P., & Kuchař, M. (2021) · Drug Testing and Analysis · doi:10.1002/dta.2950 · Cited by 67
Research works printed but not linked: 4
- Stamets, P. (1996). Psilocybin Mushrooms of the World: An Identification Guide, Ten Speed Press.
- Stijve, 1993, Macromycetes from the State of Paraná, Brazil. 4. The Psychoactive Species, Arq. Biol. Tecnol., 36, 313
- Pellegrini, 2013, Evaluation of psychoactive tryptamines in magic mushrooms and truffles by LC-MS/MS, J. Pharm. Biomed. Anal., 74, 212
- Catalfomo, 1964, The production of psilocybin in submerged culture by Psilocybe cubensis, Lloydia, 27, 53
Cited by
Cardiovascular safety of psilocybin in psychiatric practice: a narrative review
Szarpak, Ł., Pruc, M., Świeczkowski, D., Rybczynski, B., Pięta, A., & Cubała, W. J. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04151-2
Metadata
- Authors
- Sharchaton, A., Parsha, S., Azerrad, S. P., Dekel, Y., Rabah, N., Páleníček, T., & Kurzbaum, E.
- Affiliations
- Tel Hai Academic College (IL)
- University of Haifa (IL)
- Charles University (CZ)
- Corresponding author
- Kurzbaum, Eyal
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2026-07-02
- Volume
- 12
- Issue
- 7
- Pages
- 486
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC13412672
- OpenAlex
- W7167101970
- Semantic Scholar
- 549db6b548754554d7dd880c2ba446d3a00880e4
- Cited by
- 1
- References
- 24
- Citations by year
- 2026: 1
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Ministry of Innovation, Science and Technology (1001829007, 1001802444)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Fungal Biology and Applications
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- Psilocybe cubensis, psilocybin, psilocin, inter-strain variability, fruiting bodies, strain selection, controlled cultivation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions. https://app.cochat.ai/papers/10.3390/jof12070486
- The paper
- Sharchaton, A., Parsha, S., Azerrad, S. P., Dekel, Y., Rabah, N., Páleníček, T., & Kurzbaum, E. (2026). Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions. Journal of Fungi. https://doi.org/10.3390/jof12070486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.